Artwork

Content provided by EMJ. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by EMJ or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Hema Now: Episode 21 The Global Perspectives on Myeloma

32:58
 
Share
 

Manage episode 493870676 series 3412919
Content provided by EMJ. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by EMJ or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

In this episode, Jonathan Sackier welcomes Claudio Cerchione, haematologist and researcher at the Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. From his early interest in plasma cell disorders, Cerchione shares key insights into the evolution of multiple myeloma (MM) research, the rising role of minimal residual disease (MRD), and promising developments in monoclonal antibodies and CAR-T therapy. He also reflects on standout moments from recent European Hematology Association (EHA) Congress and American Society of Clinical Oncology (ASCO) Annual Meeting, and shares his hopes for the future of haematology.

Timestamps:

  • 2:14: Memorable career experiences for Claudio

  • 4:20 Biggest breakthrough in MM

  • 5:10 Interest in plasma cell disorders

  • 6:30 A surprising fact about multiple myeloma

  • 7:40 Claudio’s top choice for a dinner party guest

  • 10:30 The importance of MRD in haematology

  • 13:00 Monoclonal antibodies and CAR-T therapies

  • 19:00 Current challenges

  • 22:22 Claudio’s key EHA and ASCO takeaways

  • 28:30 Claudio’s three magic wishes

  continue reading

199 episodes

Artwork
iconShare
 
Manage episode 493870676 series 3412919
Content provided by EMJ. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by EMJ or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

In this episode, Jonathan Sackier welcomes Claudio Cerchione, haematologist and researcher at the Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. From his early interest in plasma cell disorders, Cerchione shares key insights into the evolution of multiple myeloma (MM) research, the rising role of minimal residual disease (MRD), and promising developments in monoclonal antibodies and CAR-T therapy. He also reflects on standout moments from recent European Hematology Association (EHA) Congress and American Society of Clinical Oncology (ASCO) Annual Meeting, and shares his hopes for the future of haematology.

Timestamps:

  • 2:14: Memorable career experiences for Claudio

  • 4:20 Biggest breakthrough in MM

  • 5:10 Interest in plasma cell disorders

  • 6:30 A surprising fact about multiple myeloma

  • 7:40 Claudio’s top choice for a dinner party guest

  • 10:30 The importance of MRD in haematology

  • 13:00 Monoclonal antibodies and CAR-T therapies

  • 19:00 Current challenges

  • 22:22 Claudio’s key EHA and ASCO takeaways

  • 28:30 Claudio’s three magic wishes

  continue reading

199 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play